Gastric carcinogenesis involves multiple genetic and epigenetic alterations. Epigenetic silencing of tumorrelated genes due to CpG island methylation (CIM) has been recently reported in gastric cancer, but the role in precursor lesions is not well understood. We analysed the methylation status of the tumor suppressor gene p16, the DNA mismatch repair gene hMLH1, and four CpG islands (MINT1, MINT2, MINT25, and MINT31) using methylation-specific polymerase chain reaction in 35 polypoid adenomas and 46 flat dysplasias unassociated with carcinoma, 34 early adenocarcinomas (T1N0M0) and associated adenomas/dysplasias, and corresponding adjacent non-neoplastic mucosa. The extent of CIM was defined by the fraction of methylated loci (methylation index), and compared with previously characterized genetic alterations (microsatellite instability (MSI) and APC gene mutation). We found that methylation of p16 was more frequent in adenocarcinoma-associated dysplasias/adenomas (29%) and adenocarcinomas (44%) as compared to flat dysplasias (4%) and adenomas (18%) unassociated with adenocarcinoma (P ¼ 0.001). The mean methylation index increased from normal/chronic gastritis (CG) mucosa (0.09) to intestinal metaplasia (IM) (0.16), flat dysplasias (0.40) or polypoid adenomas (0.41) unassociated with carcinoma, dysplasias/adenomas associated with carcinoma (0.44), and adenocarcinomas (0.44). There was no difference in frequencies of highlevel CpG island methylation (CIM-H, methylation index X0.5) among flat dysplasias (50%) and polypoid adenomas (51%) unassociated with carcinoma, dysplasias/adenomas associated with adenocarcinoma (47%), and adenocarcinoma (47%). CIM-H was present in 15% of IM, but not in normal/CG mucosa. There was a significant correlation between methylation of hMLH1 and high-level of microsatellite instability (MSI-H): methylation of hMLH1 was present in 71% of MSI-H tumors, but only 8% of MSI-low tumors and 13% of microsatellite-stable tumors (P ¼ 0.0001). There was no statistical difference between methylation index and APC mutation. Our results indicate that concurrent promoter methylation is an early and frequent event in gastric tumorigenesis, including both MSI-H and microsatellitestable neoplasms. Methylation of the p16 gene may contribute to the malignant transformation of gastric precursor lesions.
Introduction
Gastric cancer is one of the most common malignant neoplasms worldwide. Genetic alternations involving proto-oncogenes (K-ras and b-catenin), tumor suppressor genes (p53 and APC), cell-cycle regulator genes (E-cadherin and p16), and mismatch repair genes (hMLH1 and hMSH2) play an important role in gastric carcinogenesis (Kihana et al., 1991; Becker et al., 1994; Rhyu et al., 1994; Akiyama et al., 1996; Gunther et al., 1998; Park et al., 1999) .
Epigenetic silencing of tumor-related genes due to CpG island methylation (CIM) has been reported recently in gastric carcinoma (Toyota et al., 1999b) . CpG islands are 0.5 to 2 kb regions rich in cytosineguanine dinucleotides and are present in the 5 0 promoter region of approximately 40-50% of human genes (Momparler and Bovenzi, 2000) . Methylation of cytosines within CpG islands is associated with the loss of gene expression by repression of transcription and is observed in tumorigenesis, as well as physiological conditions such as X chromosome inactivation and aging (Jones and Laird, 1999; Li et al., 1993; Panning and Jaenisch, 1998; Baylin and Herman, 2000; Toyota and Issa, 2000; Wajed et al., 2001) .
Among methylation of various tumor-related genes, methylation of the promoter region of the hMLH1 gene, which encodes for the DNA mismatch repair protein hMLH1, is frequently present in sporadic gastric carcinomas that display the microsatellite instability (MSI) phenotype (Fleisher et al., 1999 (Fleisher et al., , 2001 Endoh et al., 2000) . Methylation of p16 gene, a cyclin-dependent kinase inhibitor, and CpG islands that are methylated in tumors (MINT) has also been found to be altered in gastric tumors (Toyota et al., 1999b; Jang et al., 2001; Waki et al., 2002) . To date, most of the methylation studies in gastric neoplasms have focused on aberrant methylation of a single gene in carcinomas (Kanai et al., 1998; Iida et al., 2002; Fujimoto et al., 2000; Tsuchiya et al., 2000; Kang et al., 2002) . Recent data, however, suggest that there is concordant methylation of multiple genes (termed CpG-island methylation phenotype, CIMP) (Toyota et al., 1999a) in carcinomas from diverse sites including uterine cervix, colorectum, biliary tree, pancreas, bladder, nasopharynx, esophagus, and stomach (Toyota et al., 1999a, b; Eads et al., 2000 Eads et al., , 2001 Kang et al., 2001; Leung et al., 2001; Maruyama et al., 2001 Maruyama et al., , 2002 Ueki et al., 2001; Virmani et al., 2001; Lee et al., 2002a, b; Kwong et al., 2002) . Concordant methylation of multiple loci has been described in 41% of gastric cancer (Toyota et al., 1999b) .
On the basis of the similarities between the morphological and genetic aspects of colorectal and gastric cancer, it has been postulated that some gastric carcinoma may arise from gastric adenomas or flat dysplasias, similar to the colorectal adenoma-carcinoma sequence (Correa, 1992; Correa and Shiao, 1994; Maesawa et al., 1995; Stadtlander and Waterbor, 1999) . The cumulative prevalence of malignant transformation of gastric dysplasia/adenoma has been reported to be greater than 10% in long-term follow-up studies (Kolodziejczyk et al., 1994; Orlowska et al., 1995) . We have previously shown that somatic APC gene mutations were more frequent in adenomas or flat dysplasias unassociated with adenocarcinoma (76%) than in adenomas/ dysplasias associated with adenocarcinoma (3%), suggesting that APC mutation contributed to less aggressive precursors (Lee et al., 2002a) . Epigenetic alterations have been acknowledged as an important mechanism contributing to gastric carcinoma progression, and previous studies have characterized epigenetic abnormalities in intestinal metaplasia (IM) and adenoma, which are precursors of invasive adenocarcinoma (Kang et al., 2001 (Kang et al., , 2003 . The role of epigenetic alterations and CIMP in the two distinct morphological precursor lesions (flat dysplasia and polypoid adenoma) with and without associated adenocarcinoma remains unclear.
The current study examines the role of methylation of multiple tumor-related genes involved in early gastric precursors including flat dysplasia and polypoid adenomas with and without an associated adenocarcinoma. We determined the temporal sequence of methylation in nonneoplastic gastric mucosa, in IM, in polypoid adenomas or flat dysplasias unassociated with carcinoma, in dysplasias/ adenomas associated with adenocarcinoma, and in adenocarcinomas to clarify the possible role of CIM in malignant transformation of gastric precursor lesions.
Materials and methods

Case selection
This study was approved by University of Texas MD Anderson Cancer Center Institutional Review Board. This study population included 35 adenomas and 46 flat dysplasias from endoscopic biopsies of patients without gastric carcinoma, and 34 adenoma/dysplasia (28 contiguous adenomas/ dysplasias and six noncontiguous adenomas/dysplasias) associated with T1N0M0 adenocarcinoma from gastrectomy specimens. Non-neoplastic gastric mucosa with IM was taken either from the surgical margins of gastrectomy specimens with T1 adenocarcinoma (four cases) or adjacent to flat dysplasia (33 cases) or adenomas (22 cases). Normal/chronic gastritis (CG) gastric mucosa was obtained from the surgical margins of specimens with T1 adenocarcinoma (30 cases) or adjacent to flat dysplasia (12 cases) or adenoma (seven cases).
These cases were retrospectively identified from the surgical pathology files of Chonnam National University Hospital in Kwangiu, South Korea, between 1996 and 2000. The patients' characteristics (age, sex, and location of neoplasm) have been reported previously (Lee et al., 2002a) . The distinction between adenoma and dysplasia was based on endoscopic findings. Gastric adenoma was defined as a polypoid, elevated or exophytic lesion, and flat dysplasia as a flat or depressed lesion.
DNA extraction
Microdissection from formalin-fixed, paraffin-embedded tissue was performed on H&E-stained slides for both tumor and non-neoplastic mucosa. In cases of adenocarcinoma associated with adenoma/dysplasia, the carcinoma and adenoma/dysplasia components were separately microdissected and analysed. Genomic DNA was extracted from microdissected tissue as described previously (Moskaluk and Kern, 1997) . In brief, microdissected tissue was treated with 50 ml of buffer containing 0.5% Tween-20 (Boehringer Mannheim, Germany), 20 mg proteinase K (Boehringer Mannheim, Germany), 50 mmol/l Trizma base at pH 8.9, and 2 mmol/l ethylenediaminetetraacetic acid and incubated at 561C for 12-18 h. Proteinase K was inactivated by incubating the samples at 1001C for 10 min.
Bisulfite treatment of DNA and methylation-specific polymerase chain reaction (MSP-PCR)
The methylation status of tumor suppressor gene p16, DNA mismatch repair gene hMLH1, and four tumor-specific CpG islands (MINT1, MINT2, MINT25, and MINT31) was determined by bisulfite treatment of DNA followed by MSP-PCR, as described previously, with modification (Herman et al., 1996) . MINT1 and MINT2 correspond to CpG islands that are in the 5 0 region of cDNAs with open-reading frames that have no known protein homology. The CpG island of MINT25 maps to chromosome 22q11-13, but the associated gene is unknown at this point. MINT31 is 2 kb upstream of the CACNA1G, a T-type calcium channel gene. Primer sequences and MSP conditions of each gene tested are summarized in Table 1 . In brief, 1 mg of microdissected genomic DNA was denatured with 2 mol/l NaOH at 371C for 10 min, followed by incubation with 3 mol/l sodium bisulfite (pH 5.0) at 501C for 16 h in the dark. After treatment, DNA was purified using the DNA cleanup kit (Promega, Madison, WI, USA) as recommended by the manufacturer, incubated with 3 mol/l NaOH at room temperature for 5 min, precipitated with 10 mol/l ammonium acetate and 100% ethanol, washed with 70% ethanol, and finally resuspended in 20 ml of distilled water. Methylation status of each gene or MINT was determined using 2 ml of bisulfite-treated DNA as template for PCR reactions using primers specific for methylated and unmethylated alleles. Amplification was carried out in a GeneAmp PCR System 9700 thermocycler (Perkin-Elmer, USA). A 10 ml aliquot of amplified PCR product was electrophoresed on 5% acrylamide gels and visualized by ethidium bromide staining. DNA from the RKO colon cancer cell line (American Type Culture Collection, Manassas, VA, USA) was used as a positive control for methylation.
Methylation index
CIM status was determined in normal/CG gastric mucosa, IM, dysplasias and adenomas, and adenocarcinomas. To determine the extent of methylation for the panel of genes and MINT loci examined, we calculated the methylation index (methylation index ¼ total number of genes and MINT loci methylated/total number of genes and MINT loci analysed) for each sample. Cases showing methylation index 0.5 or greater were classified as high-level CIM (CIM-H), those with methylation index less than 0.5 but greater than 0 as low-level CIM (CIM-L), and cases with no methylated loci at all were defined as CIM negative (CIM-N). The CIM status was correlated with genetic alterations, including APC gene mutation and MSI status, as reported previously (Lee et al., 2002a) .
Immunohistochemistry
The expression of hMLH1 protein was evaluated in 17 tumors (five dysplasias, five adenomas, and seven adenoma/dysplasiaassociated adenocarcinoma) with methylation of hMLH1, and six tumors (three dysplasias and three adenomas) without methylation of hMLH1 by immunohistochemical staining. Tissue sections (5 mm) of formalin-fixed, paraffin-embedded blocks were deparaffinized, rehydrated, rinsed with distilled water, and washed with Tris-buffered saline. Antigen retrieval was performed using a heat-induced epitope retrieval method (Bankfalvi et al., 1994) . Immunoperoxidase staining used diaminobenzidine as chromogen. Mouse monoclonal antibody to the hMLH1 gene product was used at 1:300 dilutions (Pharmingen, San Diego, CA, USA).
Statistical analysis
Statistical analyses of differences in frequencies and concordance of methylation between various genes and loci were performed using w 2 or Fisher's exact tests. Differences in mean MI were analysed using the Mann-Whitney one-way nonparametric U-test. For all of the tests, Po0.05 was regarded as statistically significant. All data were analysed with SPSS 10.1 for Windows.
Results
Methylation of CpG islands in p16 and hMLH1 genes and MINT loci Figure 1 shows examples of methylation analysis for p16 and hMLH1 genes, and for MINT1, MINT2, MINT25, and MINT31 in normal mucosa/CG, IM, dysplasias and adenomas, and early (T1N0M0) adenocarcinoma. Figure 2 summarizes the methylation data for each marker. Figure 3 shows the distribution of the number of methylated loci in the pathologic categories, and the frequencies of methylation for each marker are summarized in Table 2 .
The frequency of methylation of individual marker was variable in different histopathological categories. In mucosal specimens, methylation of MINT loci was present in 6-21% of normal/CG mucosa, and methylation of p16 and MINT CpG islands was present in 7-41% of IM. Methylation of MINT25 was more frequent in normal/CG mucosa contiguous with neoplasm (37%), and in IM (41%) than in noncontiguous normal/CG mucosa (10%), P ¼ 0.03 and 0.006, respectively (Table 2) . No methylation of hMLH1 or p16 was present in any normal/CG mucosa, and no hMLH1 methylation was present in IM.
In adenoma/dysplasia unassociated with carcinoma, the frequencies of methylation of hMLH1 and MINT loci were significantly higher than in IM (Table 2) , but there was no statistical difference in p16 methylation between IM (7%) and either dysplasia (4%, P ¼ 0.46) or adenoma (15%, P ¼ 0.2) unassociated with carcinoma. No difference in methylation frequency in each individual marker was present between flat 
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In adenoma/dysplasia associated with carcinoma, methylation of p16 was more frequent (29%) than in adenoma/dysplasia unassociated with carcinoma (9%, P ¼ 0.01). The frequency of methylation of p16 increased from dysplasia (4%) and adenoma (18%) unassociated with carcinoma, to dysplasia/adenoma associated with carcinoma (29%), to adenocarcinoma (44%), P ¼ 0.001. In contrast, there was no difference in methylation frequency of hMLH1 and MINT loci between adenoma or dysplasia unassociated with carcinoma, adenoma/dysplasia associated with adenocarcinoma, and adenocarcinoma.
Methylation index
The number of genes or loci methylated increased with the histological progression from normal/CG mucosa, to IM, adenomas or dysplasias, and adenocarcinomas ( Figure 3 ). This was represented by the mean methylation index. There was a significant difference in mean methylation index between normal mucosa (0.09) and IM (0.16, P ¼ 0.02), and in adenoma or dysplasia unassociated with carcinoma (0.41), than IM (0.16, Po0.00001), but the mean methylation index was similar in adenomas or dysplasias, and T1 adenocarcinoma (Table 3) .
Correlation of methylation was present among several sets of genes and loci in IM, dysplasia/adenomas, and adenocarcinomas (Table 4) . Methylation index greater than 0.5 (CIM-H) was seen in 15% of IM, 50% of flat dysplasias, 51% of polypoid adenomas, 47% of dysplasias/adenomas associated with carcinoma, and 47% of adenocarcinomas, but not in normal/CG mucosa ( Figure 3 and Table 3 ). There was significant concordance between methylation index and methylation of hMLH1; methylation of hMLH1 was detected in 34% of CIM-H tumors but in only 3% of CIM-L tumors (P ¼ 0.0001). However, methylation index was not correlated with methylation of p16; methylation of p16 was detected in 25% of CIM-H tumors and 17% of CIM-L tumors (P ¼ 0.3).
Correlation between the extent of CIM and other genetic alterations
We had previously determined the MSI status and APC gene mutation status (Figure 2 ) in the specimens used in this study (Lee et al., 2002a) . There was a significant correlation between aberrant DNA methylation of hMLH1 and MSI-H: methylation of hMLH1 was present in 71% of MSI-H tumors, but in only 8% of MSI-L tumors and 13% of MSS tumors (P ¼ 0.0001, Table 5 ). There was no statistically significant difference between methylation index and APC mutation status in adenomas and dysplasias unassociated with carcinoma: CIM-H was present in 67% (16 of 24) of adenomas and dysplasias without APC mutation, and in 46% (26 of 57) of adenomas and dysplasias with APC mutation (P ¼ 0.09).
Expression of hMLH1 protein by immunohistochemistry
In adenomas and dysplasia not associated with adenocarcinomas, normal expression of hMLH1 was present in five adenomas (one MSI-H, one MSI-L, and three MSS) and five MSS dysplasias with methylation of hMLH1, and in three MSS adenomas and three MSS dysplasias without methylation of hMLH1. In seven cases of adenoma/dysplasia associated with T1 adenocarcinoma, hMLH1 expression was absent in five (three MSI-H and two MSS) of six (three MSI-H and three MSS) adenoma/dysplasia components, and in four (three MSI-H and one MSS) of six (three MSI-H and three MSS) adenocarcinoma components with methylation of hMLH1 (Figure 4 ).
Discussion
Our study indicates that CIM has an important role in early gastric carcinogenesis. We found that concordant methylation of multiple genes or loci (CIM-H) was present in 47-50% of flat dysplasias and adenomas unassociated with gastric carcinomas, and also in adenomas/dysplasias associated with adenocarcinomas and in adenocarcinomas, as contrasted with only 15% of IM and no examples of normal/CG mucosa. There were no differences among methylation frequencies at MINT loci, and mean MI between gastric adenomas or Figure 1 Examples of MSP-PCR at p16, hMLH1, MINT1, MINT2, MINT25, and MINT31 in normal mucosa, IM, precursor lesion, and early adenocarcinoma. Methylation of p16, hMLH1, MINT1, MINT2, MINT25, and MINT31 was evaluated by MSP using primers for methylated (M) and unmethylated (U) alleles of bisulfite-treated DNA on 6% acrylamide gels. Gene or loci examined are indicated on the left side of each gel and samples on top of the first gel. L, designates size marker; NR1 and NR2, two normal gastric mucosas; IM, intestinal metaplasia; AD, adenoma/dysplasia associated with adenocarcinoma; CA, early adenocarcinoma; RKO, a colon cancer cell line used as a positive control, and Neg, sample without DNA used as negative control. Methylation of MINT25 is present in IM. Adenoma/dysplasia associated with adenocarcinoma (AD) and early adenocarcinoma (CA) have methylation of hMLH1, MINT1, MINT2, MINT25, and MINT31. The upper band of the double bands shown in hMLH1 and MINT2 is a spurious band appearing only on 6% acrylamide gels but not on 2% agarose gels dysplasias unassociated with carcinoma and adenomas/ dysplasias associated with adenocarcinomas. In contrast, the frequency of p16 gene methylation was significantly increased from dysplasias (4%) or adenomas (18%) unassociated with carcinoma to adenomas/ dysplasias associated with adenocarcinoma (29%) to Figure 2 Summary of CIM status; methylation status at p16, hMLH1, MINT1, MINT2, MINT25, and MINT31; APC mutation and MSI in dysplasias and adenomas unassociated with carcinoma, dysplasias/adenomas associated with carcinoma and early adenocarcinomas adenocarcinoma (44%). Thus, methylation of p16 may play a role in the malignant transformation of gastric precursor lesions. The frequency of p16 methylation in adenocarcinoma in our study is similar to that reported in invasive gastric adenocarcinomas (Toyota et al., 1999b; Jang et al., 2001; Kang et al., 2001 Kang et al., , 2003 .
Methylation of the p16 gene in nontumor gastric tissue has been described previously, but the detailed histological features of the nontumor tissue were uncharacterized (Leung et al., 2001; Waki et al., 2002) . Waki et al. (2002) have shown p16 methylation in nonneoplastic gastric epithelial cells of persons who were 45 years or older, and suggested an association between age-related methylation and gastric cancer development.
In the present study, however, we show that p16 gene methylation is present only in 7% of IM, but not in normal/CG mucosa, as has been reported previously (Jang et al., 2001; Kang et al., 2001) .
Methylation of hMLH1 has been strongly correlated with the lack of hMLH1 protein expression and MSI-H, indicating that promoter methylation is the main inactivation mechanism of the hMLH1 gene responsible for MSI-H in gastric carcinoma (Fleisher et al., 1999 (Fleisher et al., , 2001 Endoh et al., 2000; Leung et al., 2001 ). In the current study, hMLH1 was methylated at similar frequencies in both types of premalignant lesions (polypoid adenomas and flat dysplasias) as described previously by Kang et al. (2001) . We found a significant correlation between methylation of hMLH1 and MSI-H (Po0.0001) in gastric preneoplastic lesions and early adenocarcinomas. Methylation of hMLH1 has also been described in 6.3% of gastric mucosa with IM (Kang et al., 2001) and in up to 71% of nontumor mucosa surrounding foveolar type gastric adenocarcinoma , but in the current study no methylation of hMLH1 was detected in any nonneoplastic mucosa including IM. The loss of hMLH1 protein expression has been associated with methylation of hMLH1 in gastric carcinomas (Leung et al., 1999; Fleisher et al., 1999 Fleisher et al., , 2001 ), but the association in gastric preneoplastic lesions is not clear. The loss of hMLH1 protein expression was present in adenoma/dysplasia associated with T1 adenocarcinoma with methylation of hMLH1 (five of six adenoma/dysplasia components and four of six adenocarcinoma components), but not in adenoma and dysplasia unassociated with adenocarcinoma with methylation of hMLH1. The reason for this discrepancy is not clear, but it is possible that hMLH1 methylation can precede the loss of hMLH1 protein expression as demonstrated in previous study in nontumor mucosa surrounding gastric foveolar adenocarcinoma .
MINT loci were methylated in 6-21% of normal mucosa, and in 10-41% of IM. In particular, methylation of MINT25 was more frequent in normal/CG mucosa contiguous with neoplasms, and in IM than in noncontiguous normal/CG mucosa. These data are similar to previously published results that methylation of DAP-kinase, THBS1, and TIMP-3 was frequently present in CG and CG with IM (Kang et al., 2001) . In fact, CIM-H was also present in 15% of IM, again supporting the concept that concordant methylation of multiple genes may play an important role in early gastric carcinogenesis (Toyota et al., 1999b) . The accumulation of concurrent methylation in multiple genes appears to follow the CG-IM-dysplasia/adenoma-adenocarcinoma sequence, as shown in this and other studies (Kang et al., 2001 (Kang et al., , 2003 .
There are three lines of evidence indicating that not every dysplastic gastric lesions are precursor lesions for gastric carcinoma. First, gastric dysplasia can undergo spontaneous regression clinically, especially low-grade dysplastic lesions, and only 11-40% of adenoma/ dysplasia progress to carcinoma (Kamiya et al., 1982; Kolodziejczyk et al., 1994; Orlowsaka et al., 1995) . Figure 3 The numbers of gene or loci methylated in normal mucosa, IM, precursor lesion, and early adenocarcinoma. Adenoma/dysplasia unassociated or associated with carcinoma had more concordant methylation (three or more loci) as compared to normal mucosa and IM Second, APC mutations have been reported to occur more frequently in gastric adenomas than in gastric adenocarcinomas (Nakatsuru et al., 1993; Tamura et al., 1994; Maesawa et al., 1995) . In addition, somatic APC gene mutations are more frequent in adenomas or flat dysplasias unassociated with adenocarcinoma than in Figure 4 Immunohistochemical staining for hMLH1 in gastric adenoma/dysplasia associated with carcinoma. The adenoma/ dysplasia component (MSI-H with methylation of hMLH1 gene) showed no nuclear hMLH1 expression. In contrast, the carcinoma component (MSS without methylation of hMLH1 gene) indicated by an arrow showed nuclear hMLH1 expression adenomas/dysplasias associated with adenocarcinoma and adenocarcinomas (Lee et al., 2002a) . These data suggest that a large subset of adenomas/dysplasias do not progress to invasive carcinoma. In the present study, we additionally show that methylation of p16 gene is more frequent in carcinomas and their associated dysplasias/adenomas, than in dysplasias/adenomas unassociated with carcinoma. These results suggest methylation of p16 gene and lack of APC gene mutation may be an indicator of malignant transformation of gastric precursor lesions, however, a large prospective study is needed to validate this finding.
In conclusion, we found frequent concurrent CIM in gastric precursor lesions and early T1 adenocarcinoma. Our data suggest that the concordant promoter methylation play an important role in the pathogenesis of gastric precursor lesions and early gastric carcinomas. Methylation of p16 gene may play a role in the malignant transformation of gastric precursor lesions.
